Wall Street analysts forecast that Akari Therapeutics PLC (NASDAQ:AKTX) will post ($0.66) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Akari Therapeutics’ earnings. Akari Therapeutics reported earnings of ($0.09) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 633.3%. The business is expected to announce its next earnings results on Monday, June 18th.
On average, analysts expect that Akari Therapeutics will report full-year earnings of ($1.75) per share for the current financial year, with EPS estimates ranging from ($2.71) to ($1.00). For the next financial year, analysts anticipate that the firm will report earnings of ($2.21) per share, with EPS estimates ranging from ($3.42) to ($1.00). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Akari Therapeutics.
Akari Therapeutics (NASDAQ:AKTX) last announced its quarterly earnings results on Wednesday, March 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.59.
AKTX has been the subject of several recent research reports. Canaccord Genuity reduced their price target on Akari Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, March 29th. ValuEngine upgraded Akari Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $4.63.
Akari Therapeutics traded up $0.03, hitting $1.89, during trading on Thursday, MarketBeat.com reports. 20,700 shares of the company traded hands, compared to its average volume of 118,082. The stock has a market cap of $22.73 million, a P/E ratio of -6.75 and a beta of -7.65. Akari Therapeutics has a 1 year low of $1.70 and a 1 year high of $11.95.
Several institutional investors have recently bought and sold shares of AKTX. AWM Investment Company Inc. purchased a new stake in shares of Akari Therapeutics in the fourth quarter valued at approximately $2,962,000. Millennium Management LLC increased its position in shares of Akari Therapeutics by 125.0% in the fourth quarter. Millennium Management LLC now owns 260,020 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 144,477 shares in the last quarter. Endurant Capital Management LP purchased a new stake in shares of Akari Therapeutics in the fourth quarter valued at approximately $871,000. Finally, Hikari Power Ltd increased its position in shares of Akari Therapeutics by 320.5% in the first quarter. Hikari Power Ltd now owns 636,343 shares of the biopharmaceutical company’s stock valued at $1,158,000 after buying an additional 485,009 shares in the last quarter. Institutional investors and hedge funds own 18.52% of the company’s stock.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.